MACROGEN, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20,050 KRW | +0.80% |
|
+1.37% | -4.52% |
| 2023 | Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. | CI |
| 2023 | Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. | CI |
| Sales 2024 * | 148B 108M | Sales 2025 * | 165B 120M | Capitalization | 198B 144M |
|---|---|---|---|---|---|
| Net income 2024 * | 10B 7.27M | Net income 2025 * | 14B 10.18M | EV / Sales 2024 * | 1.42 x |
| Net Debt 2024 * | 11B 8M | Net Debt 2025 * | 17B 12.36M | EV / Sales 2025 * | 1.31 x |
| P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
15.4
x | Employees | 532 |
| Yield 2024 * |
1.51% | Yield 2025 * |
1.51% | Free-Float | 80.62% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.55% | ||
| 1 week | +0.56% | ||
| Current month | -11.80% | ||
| 1 month | -15.36% | ||
| 3 months | -6.62% | ||
| 6 months | +22.17% | ||
| Current year | -5.29% |
1 week
19 350.00
20 150.00
1 month
18 960.0023 500.00
Current year
18 960.0026 700.00
1 year
15 470.0029 900.00
3 years
15 470.0040 000.00
5 years
15 470.0049 200.00
10 years
15 470.0054 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Su-Gang Lee
CEO | Chief Executive Officer | 58 | - |
Jong-Yeon Shin
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
Chang-Hoon Kim
BRD | Director/Board Member | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeong-Sun Seo
CHM | Chairman | 71 | - |
Hyung-Tae Kim
BRD | Director/Board Member | 61 | - |
Hee-Min Kwon
BRD | Director/Board Member | 72 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 20,050 | +0.80% | 26 736 |
| 24-04-25 | 19,890 | -0.55% | 14,605 |
| 24-04-24 | 20,000 | +0.35% | 20,842 |
| 24-04-23 | 19,930 | +1.12% | 26,785 |
| 24-04-22 | 19,710 | +1.86% | 25,976 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
Macrogen, Inc. is a Korea-based company mainly engaged in the customized transgenic and other services in the field of biomedical research. The Company operates its business through four divisions: deoxyribonucleic acid (DNA) sequencing division, DNA chips division, transgenic and knockout mouse division and oligonucleotide DNA division. Its DNA sequencing division provides genome sequencing analysis services. Its DNA chips division develops DNA chips products, such as Illumina chips, MacArray chips and customized chips. Its transgenic and knockout mouse division offers gene engineering services. Its oligonucleotide DNA division offers oligonucleotide DNA manufacturing services. The Company operates its business within domestic market and in overseas markets.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19,890
KRW
Average target price
30,000
KRW
Spread / Average Target
+50.83%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -5.29% | 145M | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +47.53% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
- Stock Market
- Equities
- A038290 Stock
